Invectys well poised to bring its anti-HLA-G CAR-T cells to clinical trials …
Invectys reports in vivo efficacy of its pan anti-tumor anti-HLA-G CAR-T cells These results open new perspectives in oncology for targeting cancer through HLA-G,…
Invectys Strengthens Advisory Board with the Appointment of Dennis J. Purcell, Life Sciences Industry Veteran and Founder of Aisling Capital LLC Paris, France, May…
Invectys publishes positive clinical results for its INVAC-1 Phase I Study in Clinical Cancer Research With an extended Phase I and a new delivery method…
Invectys : lutter contre toutes les formes de cancers Avec 382 000 nouveaux cas et 157 400 décès par an, le cancer demeure une priorité absolue en matière de…
8th International Conference on HLA-G July 8th – 9th 2019 Ministère de la Santé et des Solidarités, Paris, France Invectys will be attending the 8th International…
Invectys élu « meilleur projet – jeune entreprise » 2019 par le Board international de MATWIN Invectys, société biopharmaceutique développant des thérapies…
Healthtech Investor Day June 24th – 25th, 2019 The Peninsula Paris, Paris, France Pierre Langlade-Demoyen, our CEO, will be representing Invectys…
